MONTREAL, Sept. 06, 2018 (GLOBE NEWSWIRE) — Pediapharm, Inc. (“Pediapharm”) (TSXV: PDP, OTCQX: PDDPF) is pleased to announce that it has entered into definitive agreements to acquire two speciality pharmaceutical companies and also intends to complete a private placement offering for up to CDN$60 million.

Pediapharm logo

PEDIAPHARM is the only Canadian specialty pharmaceutical company dedicated to serving the needs of the pediatric community.

Medexus logo

MEDEXUS is a Canadian specialty pharmaceutical company focused on the licensing, registration, marketing, sales and distribution of innovative pharmaceutical products in Canada.

Medexus Pharm logo

MEDEXUS PHARMA is a specialty pharmaceutical company focusing on the development and commercialization of treatments for autoimmune diseases and oncology in the United States.


What's New

September 12, 2019
Medexus Reports Health Quality Ontario Recommends Gliolan® for Public Reimbursement
Read More >

August 22, 2019
Medexus Pharmaceuticals Reports Operating and Financial Results for the First Quarter of Fiscal 2020
Read More >

August 16, 2019
Medexus Pharmaceuticals Schedules First Quarter Fiscal 2020 Conference Call
Read More >


Medexus Pharmaceuticals Inc., D, TSXV